Aardark Therapeutics

San Diego, United States Founded: 2017 • Age: 9 yrs Listed
Small molecule therapeutics for obesity and metabolic disorders are developed.

About Aardark Therapeutics

Aardark Therapeutics is a publicly listed company based in San Diego (United States) founded in 2017. Small molecule therapeutics for obesity and metabolic disorders are developed. Aardark Therapeutics has raised $138 million across 4 funding rounds from investors including Sorrento Therapeutics, Cantor and Tetragon. The company has 22 employees. Its chief executive, as recorded, is Tien Lee. Aardark Therapeutics offers products and services including ARD-101. Its focus areas include Life Sciences, Obesity and Drugs. Its legal entity is AARDVARK THERAPEUTICS, INC. Its competitors include Altimmune, Carmot and BioAge Labs; 3 of its 3 listed competitors have raised funding.

Company details

Provider of small molecules therapeutics for treating obesity and rare genetic metabolic disorders. Their lead candidate, ARD-101 is an oral composition that selectively disrupts hunger signaling and regulates energy homeostasis. The candidate helps through increasing metabolic rate, interfering with nutrient absorption, or directly modifying CNS pathways, all of which are related to undesirable off-target effects.

  • Headquarters San Diego, United States
  • Employees 22
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website aardvarktherapeutics.com
  • Social LinkedIn Facebook Instagram
  • Legal Name Aardvark Therapeutics, Inc.
Operational Areas
Key Metrics
  • Net Profit
    -$57.59 M (USD)
    -179.73
    as on Dec 31, 2025
  • EBITDA
    -$62.69 M (USD)
    -175.33
    as on Dec 31, 2025
  • Total Equity Funding
    $138M (USD)

    in 4 rounds

  • Latest Funding Round
    $85M (USD), Series C

    May 2024

  • Investors
  • Employee Count
    22

Products & Services of Aardark Therapeutics

Aardark Therapeutics offers a comprehensive portfolio of products and services, including ARD-101.

ARD-101
Drug Therapy

Oral drug activating receptors to suppress hunger for rare diseases

Funding Insights of Aardark Therapeutics

Aardark Therapeutics has successfully raised a total of $138M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $85 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $138M
  • Total Rounds 4
  • Last Round Series C β€” $85M
  • First Round $9M

    (May 2019)

  • Investors Count 17

All 4 funding rounds of Aardark Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
May 2024$85MSeries C–Decheng Capital
Jun 2021$29MSeries B–Sorrento Therapeutics
Nov 2019$15MSeries A–Vickers Venture Partners, Premier Partners
May 2019$9MSeries A––
–
Valuation history

17 investors in total: 17 institutional.

Investors in Aardark Therapeutics

Aardark Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Sorrento Therapeutics, Cantor and Tetragon.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on life science and technology sectors
decheng.comShanghai, China
Investments in healthcare companies are made by SymBiosis.
symbiosis.vcBentonville, United States
Investment in early-stage companies across AI, biotech, and cleantech sectors with access to global resources.
lgtechventures.com
Growth-stage venture capital is invested in Singapore and China.
vickersventure.comSingapore, Singapore
Private equity & venture capital firm
premierpartners.co.krSeoul, South Korea
bnhinv.com
Venture capital fund focused on tech startups
koreaomega.co.krSeoul, South Korea
Manages diversified investment portfolios across various asset classes.
1997cormorant.comBoston, United States
Diversified investment management services are offered across multiple asset classes.
2005tetragoninv.comNew York, United States
Premium access

Investor details for Aardark Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Aardark Therapeutics

20 people are tracked at Aardark Therapeutics (7 in leadership, 11 in board & advisors, 2 in team); the tracked headcount is 22.

NameRoleGroup
Tien Lee
CEOLeadership
Andreas Niethammer
Chief Medical OfficerLeadership
Bryan Jones
COOLeadership
Shital Kalariya
Senior Medical DirectorLeadership
Nelson Sun
CFOLeadership
Danny Villeneuve
Chief Commercial Officer (cco)Leadership
Manasi Sinha Jaiman
Chief Medical OfficerLeadership
Jeffrey Chi
DirectorBoard & advisors
Stephen V. Faraone
AdvisorBoard & advisors
Larry Cheskin
AdvisorBoard & advisors
Zachary Hornby
DirectorBoard & advisors
Jerold Chun
AdvisorBoard & advisors
Henry Ji
DirectorBoard & advisors
Ralph A. DeFronzo
AdvisorBoard & advisors
Jerel A. Banks
DirectorBoard & advisors
Sheila Gujrathi
AdvisorBoard & advisors
Kim Janda
AdvisorBoard & advisors
Rohit Loomba
AdvisorBoard & advisors
Emily Arsenault
Finance & Accounting ConsultantTeam
Jeff Oster
General CounselTeam
Premium access

Complete people profiles for Aardark Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Aardark Therapeutics

Aardark Therapeutics is a publicly listed company on the NASDAQ with ticker symbol AARD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date13 Feb 2025
  • Listed onNASDAQ: AARD
  • Listed entityAardvark Therapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS0029421007
  • Share price$4.04 (-9.21% on the day) · 2026-10-13
  • Market capitalisation$88.4M
  • EPS (diluted, trailing year)$-3.21
  • Volume (last session)218,304

Financials of Aardark Therapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-$57.6M-$62.7M
2024-$20.6M-$22.8M
2023-$7.2M-$7.3M
2022-$13.6M-$11.2M
Premium access

Detailed financial statements for Aardark Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Aardark Therapeutics

4 dated milestones of Aardark Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.

  1. Founded Aardark Therapeutics is founded.
  2. Funding First funding round of $9.0M.
  3. Funding Latest funding round, Series C, of $85.0M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Aardark Therapeutics

Aardark Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Altimmune, Carmot and BioAge Labs.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
altimmune.com1997Gaithersburg, United States$58M17
Vaccines for infectious diseases and solid tumors are developed.
carmot.us2008Berkeley, United States$385.52M
Disease-modifying therapies for metabolic diseases are developed.
bioagelabs.com2015Vallejo, United States$293.9M43
Bioinformatics platform is provided for biomarkers and drug discovery.
Premium access

Detailed competitors of Aardark Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Aardark Therapeutics

The website of Aardark Therapeutics (aardvarktherapeutics.com) receives about 5.7K visits a month.

  • Monthly visits
    5.7K

    ▲ 40.8% vs previous month

Similar websites

Websites whose visitors overlap most with Aardark Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
truvianhealth.com
100%
4.2K#4,492,336View details
latitudepharma.com
100%
680.7KView details
carihealth.com
99%
View details
clinicomp.com
98%
#523,501View details
ambrx.com
98%
1.7K#3,844,291View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 21 similar websites and full traffic analytics for Aardark Therapeutics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 21 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Obesity

3 companies that operate in the same segment as Aardark Therapeutics (Obesity) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Bioinformatics platform is provided for biomarkers and drug discovery.
2015Vallejo, California, United StatesUSD 293.9 MUSD 8.99 M64
Disease-modifying therapies for metabolic diseases are developed.
2008Berkeley, California, United StatesUSD 385.52 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Aardark Therapeutics

Premium access

Complete news archive for Aardark Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aardark Therapeutics

Aardark Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Aardark Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Tien Lee is the CEO of Aardark Therapeutics, as recorded in our data.

Aardark Therapeutics is a funded company, having raised a total of $138M across 4 funding rounds to date. The company's 1st funding round was a Series A of $9M, raised on May 2019.

Aardark Therapeutics has 22 employees.

Provider of small molecules therapeutics for treating obesity and rare genetic metabolic disorders. Their lead candidate, ARD-101 is an oral composition that selectively disrupts hunger signaling and regulates energy homeostasis. The candidate helps through increasing metabolic rate, interfering with nutrient absorption, or directly modifying CNS pathways, all of which are related to undesirable off-target effects.

Aardark Therapeutics's top competitors include BioAge Labs, Carmot and Altimmune.

Aardark Therapeutics offers ARD-101.

Yes, Aardark Therapeutics is publicly traded on NASDAQ under the ticker symbol AARD.

Aardark Therapeutics has 17 investors. Key investors include Sorrento Therapeutics, Cantor, Tetragon, Decheng Capital, and Cormorant.

Aardark Therapeutics operates through Aardvark Therapeutics, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available